<DOC>
	<DOCNO>NCT02360579</DOCNO>
	<brief_summary>Prospective , 3-cohort interventional study evaluate autologous tumor infiltrate lymphocyte ( TIL ) infusion ( LN-144 ) follow IL-2 non-myeloablative chemotherapy preparative regimen treatment patient metastatic melanoma .</brief_summary>
	<brief_title>Study LN-144 , Autologous Tumor Infiltrating Lymphocytes , Treatment Patients With Metastatic Melanoma</brief_title>
	<detailed_description>LN-144 autologous adoptive cell transfer therapy utilize autologous TIL manufacturing process , originally develop NCI , treatment patient metastatic melanoma . The cell transfer therapy use study involve patient receive lymphocyte deplete preparative regimen , follow infusion autologous TIL follow administration regimen IL-2 .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>To eligible study , patient must meet ALL follow criterion prior enrollment 1 . Patients must measurable metastatic melanoma least one lesion resectable TIL generation . 2 . Patients must undergo least one prior systemic treatment metastatic melanoma . 3 . Patients must either progressive disease response ( i.e , PR CR ) receive completion recent prior treatment . 4 . Patients must great 18 year age time consent . Enrollment patient great 65 year age do consultation Medical Monitor . 5 . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . In opinion Investigator , patient must capable participate complete study procedure . 7 . Patients child bearing age potential must willing practice birth control treatment four month receive protocol relate therapy . 8 . Patients must serum absolute neutrophil count ( ANC ) great 1000/mm3 , hemoglobin great 9.0 g/dL , platelet count great 100,000/mm3 . 9 . Patients must serum ALT/SGPT AST/SGOT less three time upper limit normal ( &lt; 3x ULN ) , calculate creatinine clearance great 50 mL/min ( &gt; 50 mL/min ) , total bilirubin less equal 2 mg/dL ( ≤ 2 mg/dL ) . Patients Gilbert 's Syndrome must total bilirubin less 3 mg/dL ( &lt; 3 mg/dL ) . 10 . Patients must seronegative HIV antibody , hepatitis B antigen , hepatitis C antibody antigen . 11 . Patients must EBV viral capsid antigen ( VCA ) IgG positive and/or , Epstein Barr nuclear antigen ( EBNA ) IgG positive , clinical evidence active EBV infection . 12 . Patients must receive systemic chemotherapy immune therapy 2 week ( targeted therapy ) 4 week ( anticancer therapy ) time enrollment , must intention receive nonprotocol systemic anticancer chemotherapy immune therapy study period . 13 . Patients document Grade 2 great diarrhea colitis result previous treatment ipilimumab , tremelimumab , antiPD1 antiPDL1 antibody must asymptomatic least 6 month normal colonoscopy post treatment , uninflamed mucosa visual assessment . 14 . Patients must ability understand requirement study , provide write informed consent evidence signature inform consent form ( ICF ) approve institutional review board ( IRB ) , agree abide study restriction return site require assessment . 15 . Patients provide write authorization use disclosure protect health information . Exclusion Criteria Patients meet ANY follow criterion exclude study : 1 . Patients melanoma uveal/ocular origin 2 . Patients receive prior cell transfer therapy include nonmyeloablative myeloablative chemotherapy regimen ( applicable patient retreatment Cohort 3 ) . 3 . Patients three active brain metastasis . Note : Patients one two untreated inadequately treat brain lesion three adequately treat brain metastasis may eligible . If lesion symptomatic great equal 1 cm , lesion must definitively treat stable one month . Brain metastases significant edema hemorrhage metastasis large 2 cm exclude . 4 . Patients pregnant breastfeeding . 5 . Patients systemic steroid therapy regimen define need chronic steroid use least seven day dose great 10 mg prednisone equivalent per day . 6 . Patients active systemic infection , coagulation disorder active major medical illness cardiovascular , respiratory immune system , evidence medical history positive stress thallium comparable test , myocardial infarction , cardiac arrhythmia , obstructive restrictive pulmonary disease . 7 . Patients form primary immunodeficiency ( Severe Combined Immunodeficiency Disease AIDS ) . 8 . Patients history severe immediate hypersensitivity reaction IL2 , fludarabine , cyclophosphamide . 9 . Patients history coronary revascularization ischemic symptom . 10 . Patients estimate glomerular filtration rate ( eGFR ) less 40 mL/min use CockcroftGault formula Screening endstage renal disorder require hemodialysis . 11 . Patients LVEF le 45 % . ( Older patient [ 60 70 year ] , must receive echocardiogram within previous 60 day demonstrate LVEF ≥ 45 % ) . 12 . Patients document FEV1 ( forced expiratory volume one second ) less equal 60 % 13 . Patients another primary malignancy within previous three year ( exception carcinoma situ breast , urothelial cancer situ , nonmelanoma skin cancer adequately treat ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Autologous Adoptive Cell Transfer</keyword>
	<keyword>Autologous Adoptive Cell Therapy</keyword>
	<keyword>Cellular Immuno-therapy</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Tumor Infiltrating Lymphocytes</keyword>
	<keyword>TIL</keyword>
	<keyword>LN-144</keyword>
	<keyword>IL-2</keyword>
	<keyword>Melanoma</keyword>
</DOC>